Some of the world’s most powerful pharmaceutical companies backed down on planned price increases following a new transparency law in California and social media hectoring from President Donald Trump.
Healthcare takes blame for disappointing Q2 for Publicis Groupe
Directing its reps to call on GPs with little to no opioid experience, Purdue introduced aggressive promotional tactics into the prescription opioid marketing playbook.
Did the market overreact to Biogen’s Alzheimer’s data?